Manufatura aditiva farmacêutica para a personalização de terapias humanas e veterinárias
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
This study aimed to develop and characterise a three-dimensional printing-based
pharmaceutical platform for the production of personalised oral dosage forms containing
atenolol as a model drug, intended to investigate therapeutic individualisation strategies
across different clinical settings, encompassing both human and veterinary applications.
Conceptual prototypes of pharmaceutical scaffolds were fabricated from PLA, PVA and TPU
filaments using fused deposition modelling (FDM), with parametrically adjustable geometry,
dimensions and internal volume, enabling modulation of the active pharmaceutical
ingredient (API) loading capacity. An automated semi-solid extrusion system based on an
in-house developed G-code was implemented, integrating geometric parameters with
personalised dosing requirements. Among the materials evaluated, PLA scaffolds exhibited
the highest structural fidelity to the digital designs, accurately reproducing the intended
external dimensions, geometry and internal volume for drug incorporation. The results
demonstrated efficient incorporation of the pharmaceutical formulation into the printed
scaffolds. For the human model, the mean mass gain was 99.70 ± 5.03%, with a mean
loading efficiency of 92.66 ± 4.67% and a mean atenolol content of 92.26 ± 3.81% (CV =
4.13%), indicating good uniformity among the printed units. For the veterinary scaffolds, the
mean mass gain was 204.25 ± 5.51%, with a mean loading efficiency of 107.50 ± 2.90%
and a mean atenolol content of 92.05 ± 3.21% (CV = 3.49%). These findings demonstrate
satisfactory control over both the manufacturing process and the incorporation of the model
drug through semi-solid extrusion three-dimensional printing. Overall, the findings support
the potential of three-dimensional printing as an emerging and promising technology for the
on-demand manufacture of medicines, with the capacity to improve dosing accuracy,
increase therapeutic flexibility and facilitate the decentralisation of pharmaceutical
manufacturing. Consequently, this study contributes to the advancement of personalised pharmaceutical manufacturing and precision medicine by integrating digital design, process
automation and quality control within a single technological platform
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Embargado

